• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

SARM1 Forefronts Research into Major Neurological Diseases

by Bellbrook Labs / Monday, 19 December 2022 / Published in Emerging Targets, Innate Immunity, Neurodegenerative Diseases
SARM1 Causes Axonal Death

SARM1 [Sterile alpha & toll/interleukin receptor (TIR) motif-containing protein 1] consists of a N-terminal mitochondrial localization sequence (NLS), an autoinhibitory HEAT/armadillo (ARM) domain, two tandem sterile alpha motif domains (SAMs), and a C-terminal toll/interleukin receptor domain (TIR). It is a human toll like receptor (TLR) adaptor protein. TLR adaptors (MYD88, MAL, TRIF, & TRAM) usually activate the NF kappa beta signaling pathway or MAPK cascade with TIR-TIR interaction. SARM1 is an exception.

SARM1 acts to repress NF kappa beta signaling, negatively regulates TRIF mediated interferon beta production, and interacts with TRIF and MYD88 to suppress AP-1 expression. In this way, it more closely resembles the TIR proteins that pathogenic bacteria employ to evade innate immune detection. It differs from its TLR adaptor protein family members because its TIR domain functions as a NADase. Perhaps, in the distant past, SARM1 entered eukaryotic genomes via lateral gene transfer.1

SARM1’s Role in Innate Immunity

In humans, SARM1 is expressed in many tissues, being most abundant in liver, kidney, T cells, and the CNS. However, since it is primarily expressed in the central nervous system and its NADase initiates self-destruction in neural axons, it is being closely examined for its role in a host of neurological diseases. There is now evidence to implicate SARM1 in Alzheimer’s disease (AD), Parkinson’s disease (PD), brain and spinal cord traumatic injury (TBI), and peripheral neuropathy.1

SARM1 Function & Dysfunction

SARM1 self-assembles into an octamer. This octameric conformation consists of an inner skeleton, arising from adjacent SAM-SAM domain association, and an outer skeleton, resulting from adjacent ARM-TIR association. Under nominal conditions of high NAD+ abundance, NAD+ binds to ARM to conformationally ensure its stable, tight association with TIR. Under these circumstances, the NADase activity of SARM1 is inactive. When axonal injury or trauma occurs, impairment of NMNAT2 mediated conversion of NMN to NAD+ and/or shifting cellular ratios of NMN to NAD+ higher causes this octameric configuration to open up. The ARMs preferentially bind to the NMN and release their TIR partners. The TIRs swing away from ARMs via their SAM-SAM hinges. As a result, TIRs are free to multimerize and hydrolyze NAD+. When active in neurons, SARM1 cleaves NAD+ into nicotinamide, ADP-ribose (ADPR), and cyclic ADPR, depleting this vital electron carrier and causing cell death by energy depletion.2

Wallerian Degeneration & Neurological Diseases

Axonal death as the result of trauma was first recognized as Wallerian degeneration. In a limited way, if axons become damaged, their efficient removal and replacement are crucial. Short-lived chemical toxicity, neurotropic viral damage, or physical destruction requires demolition, clearance, and reconstruction.

During development, there is emerging evidence that SARM1 plays important roles in the shaping and elaboration of neural architecture. However, after maturity, dysregulated axon death contributes to neurological disease. SARM1 knock out/null neurons in culture and those of genotypically identical mice can survive chemical insults (by rotenone, CCCP, etc.) that would kill cells bearing wild type SARM1. Results from haploinsufficiency experiments in mice and genetic variants in human patients have revealed that downward modulation of SARM1 activity can be enough to mitigate pathological axon destruction. Small molecular SARM1 inhibitors are now showing promise, treating AD, PD, TBI, chemotherapy-induced neurotoxicity, and peripheral neuropathy.3,4

In the 20 years since SARM1’s discovery, it has advanced to the forefront of research into the causes of major neurological diseases.

References

    1. Hopkins, E.L. et al. (2021) A Novel NAD Signaling Mechanism in Axon Degeneration and its Relationship to Innate Immunity. Front. Mol. Biosci. 8:703532. Review. https://doi.org/10.3389/fmolb.2021.703532
    2. Sporny, M. et al. (2020) Structural basis for SARM1 inhibition and activation under energetic stress. eLife 2020;9:e62021. Review. https://doi.org/10.7554/eLife.62021
    3. Figley, D. and DiAntonio, A. (2020) The SARM1 Axon Degeneration Pathway: Control of the NAD+ Metabolome Regulates Axon Survival in Health and Disease. Curr Opin Neurobiol. 2020 Aug; 63: 59–66. Review. https://doi.org/10.1016/j.conb.2020.02.012
    4. Waller, T.J, and Collins, C.A. (2022) Multifaceted roles of SARM1 in axon degeneration and signaling. Front. Cell. Neurosci. 16:958900. Review. https://doi.org/10.3389/fncel.2022.958900
Tagged under: Innate Immunity, neurodegenerative disease, neurological disease, neuronal cell death, SARM1

What you can read next

Cancer Cell T Cell CD39 Activity Assay
Immuno-Oncology Drug Discovery: A CD39 Activity Assay for a Promising Target
Researcher working on MAPK1 pathway
MAPK1, An Elusive Regulator of Innate Immunity
EZH2 Methyltransferase Inhibitors Hold Promise for Combating Neuropathic Pain

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SIRT2 Affects Neurodegenerative Diseases

    SIRT2 Isoforms in Neurodegenerative Diseases & Cancer

    Silent information regulator type 2 (Sirtuin 2 ...
  • Patient With WRN Helicase Syndrome

    Can WRN Helicase Inhibitors Treat MSI-H Cancers?

    Over 100 years ago, Otto Werner first character...
  • NSP16 Target for COVID-19 Therapeutics

    NSP16 Shows Promise for Anti-Viral Therapeutics

    SARS-CoV-2 virus (Covid-19) possesses one of th...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP